PURPOSE: To evaluate the effects of single-nucleotide polymorphisms (SNP) in microRNA-related genes on clinical outcomes in patients with colorectal cancer (CRC) receiving first-line fluoropyrimidine-based chemotherapy. EXPERIMENTAL DESIGN: Forty-one SNPs in 26 microRNA-related genes were genotyped in 1,097 patients with CRC recruited at the University of Texas MD Anderson Cancer Center (Houston, TX). Patients were enrolled between 1990 and 2008 and last follow-up was in 2010. The associations between genotypes and recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS) stratified by clinical stage were analyzed in 741 newly diagnosed patients (diagnosed within 1 year) and replicated the findings in an additional 356 patients. RESULTS: In patients with stage III disease, mir608: rs4919510 was associated with increased risk for both recurrence [HR, 2.72; 95% confidence interval (CI), 1.38-5.33] and death (HR, 3.53; 95%CI, 1.42-8.73). The associations were confirmed in the replication set, and the combined HRs for training and replication sets were 1.65 (95% CI, 1.13-2.41) for recurrence and 1.96 (95% CI, 1.19-3.21) for death, respectively. The mir219-1:rs213210 showed consistent association with death in the training set (HR, 3.86; 95% CI, 1.33-11.22), the replication set (HR, 3.33; 95% CI, 1.39-7.98), and combined data set (HR, 3.22; 95% CI, 1.70-6.10). In combined analysis of these two SNPs, patients carrying the variant genotypes at both sites exhibited a 5.6-fold increased risk of death. CONCLUSION: Genetic polymorphisms in the microRNA pathway may predict prognosis in patients with stage III CRC treated with fluoropyrimidine-based chemotherapy.
PURPOSE: To evaluate the effects of single-nucleotide polymorphisms (SNP) in microRNA-related genes on clinical outcomes in patients with colorectal cancer (CRC) receiving first-line fluoropyrimidine-based chemotherapy. EXPERIMENTAL DESIGN: Forty-one SNPs in 26 microRNA-related genes were genotyped in 1,097 patients with CRC recruited at the University of Texas MD Anderson Cancer Center (Houston, TX). Patients were enrolled between 1990 and 2008 and last follow-up was in 2010. The associations between genotypes and recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS) stratified by clinical stage were analyzed in 741 newly diagnosed patients (diagnosed within 1 year) and replicated the findings in an additional 356 patients. RESULTS: In patients with stage III disease, mir608: rs4919510 was associated with increased risk for both recurrence [HR, 2.72; 95% confidence interval (CI), 1.38-5.33] and death (HR, 3.53; 95%CI, 1.42-8.73). The associations were confirmed in the replication set, and the combined HRs for training and replication sets were 1.65 (95% CI, 1.13-2.41) for recurrence and 1.96 (95% CI, 1.19-3.21) for death, respectively. The mir219-1:rs213210 showed consistent association with death in the training set (HR, 3.86; 95% CI, 1.33-11.22), the replication set (HR, 3.33; 95% CI, 1.39-7.98), and combined data set (HR, 3.22; 95% CI, 1.70-6.10). In combined analysis of these two SNPs, patients carrying the variant genotypes at both sites exhibited a 5.6-fold increased risk of death. CONCLUSION: Genetic polymorphisms in the microRNA pathway may predict prognosis in patients with stage III CRC treated with fluoropyrimidine-based chemotherapy.
Authors: V Boni; R Zarate; J C Villa; E Bandrés; M A Gomez; E Maiello; J Garcia-Foncillas; E Aranda Journal: Pharmacogenomics J Date: 2010-06-29 Impact factor: 3.550
Authors: David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling Journal: Lancet Date: 2010-03-20 Impact factor: 79.321
Authors: Sonia A Melo; Catia Moutinho; Santiago Ropero; George A Calin; Simona Rossi; Riccardo Spizzo; Agustin F Fernandez; Veronica Davalos; Alberto Villanueva; Guillermo Montoya; Hiroyuki Yamamoto; Simo Schwartz; Manel Esteller Journal: Cancer Cell Date: 2010-10-19 Impact factor: 31.743
Authors: Ian P M Tomlinson; Luis G Carvajal-Carmona; Sara E Dobbins; Albert Tenesa; Angela M Jones; Kimberley Howarth; Claire Palles; Peter Broderick; Emma E M Jaeger; Susan Farrington; Annabelle Lewis; James G D Prendergast; Alan M Pittman; Evropi Theodoratou; Bianca Olver; Marion Walker; Steven Penegar; Ella Barclay; Nicola Whiffin; Lynn Martin; Stephane Ballereau; Amy Lloyd; Maggie Gorman; Steven Lubbe; Bryan Howie; Jonathan Marchini; Clara Ruiz-Ponte; Ceres Fernandez-Rozadilla; Antoni Castells; Angel Carracedo; Sergi Castellvi-Bel; David Duggan; David Conti; Jean-Baptiste Cazier; Harry Campbell; Oliver Sieber; Lara Lipton; Peter Gibbs; Nicholas G Martin; Grant W Montgomery; Joanne Young; Paul N Baird; Steven Gallinger; Polly Newcomb; John Hopper; Mark A Jenkins; Lauri A Aaltonen; David J Kerr; Jeremy Cheadle; Paul Pharoah; Graham Casey; Richard S Houlston; Malcolm G Dunlop Journal: PLoS Genet Date: 2011-06-02 Impact factor: 5.917
Authors: Rodolfo Iuliano; Marco Flavio Michele Vismara; Vincenzo Dattilo; Francesco Trapasso; Francesco Baudi; Nicola Perrotti Journal: Biomed Res Int Date: 2013-03-19 Impact factor: 3.411